Below are the most recent publications written about "Watchful Waiting" by people in Profiles.
-
Bernhardt M, Weinhold L, Bremmer F, Chan E, Cheng L, Collins K, Downes M, Greenland N, Hommerding O, Iczkowski KA, Jufe L, Kreft T, van Leenders G, Oxley J, Perry-Keene J, Reis H, Schmid M, Tsuzuki T, Wobker S, Wiliamson SR, Kweldam C, Kristiansen G. Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance. Histopathology. 2025 Mar; 86(4):627-639.
-
Lasmanovich R, Shvero A, Kleinmann N. Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance. Curr Opin Urol. 2025 01 01; 35(1):68-74.
-
Al Tannir AH, Tentis M, Maring M, Patin B, Biesboer EA, Golestani S, Pokrzywa CJ, Peschman J, Murphy PB, Morris RS, Carver TW, de Moya MA. Can Concurrent Traumatic Hemopneumothorax be Safely Observed? J Surg Res. 2024 12; 304:400-407.
-
Ross AE, Iwata KK, Elsouda D, Hairston J, Russell D, Davicioni E, Proudfoot JA, Shore ND, Schaeffer EM. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance. JCO Precis Oncol. 2024 04; 8:e2300603.
-
Shore ND, Cooperberg MR, Tomlins SA. Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply. JAMA Oncol. 2023 01 01; 9(1):150-151.
-
Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136.
-
Chandrasekar T, Bowler N, Schneider A, Goldberg H, Mark JR, Trabulsi EJ, Lallas CD, Gomella LG. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology. 2021 09; 155:101-109.
-
Lawrence AE, Saito J, Onwuka A, Port E, Bowder A, Courtney C, Deans KJ, Downard CD, Duran YK, Fallat ME, Fraser JD, Gadepalli S, Kabre R, Kalbfell EL, Knaus ME, Kohler J, Lal D, Landman MP, Leys CM, Lu P, Mak GZ, Markel T, Merchant N, Nguyen T, Pilkington M, Rymeski B, Sato TT, St Peter SD, Wright T, Minneci PC, Grabowski JE. Management of Pediatric Breast Masses: A Multi-institutional Retrospective Cohort Study. J Surg Res. 2021 08; 264:309-315.
-
Czaja RC, Tarima S, Wu R, Palagnmonthip W, Iczkowski KA. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer. Ann Diagn Pathol. 2021 Jun; 52:151725.
-
Sanford T, Gomella PT, Siddiqui R, Su D, An JY, Bratslavsky G, Ball MW, Linehan WM, Metwalli AR. Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urol Oncol. 2021 02; 39(2):134.e1-134.e8.